The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Given the probability of trial success and current valuation, we rate the ATYR stock 'Hold' as risk and reward appear ...

Despite the well-recognized involvement of immunoglobulin (Ig) A in mucosal immunity, the function of its receptor ... production of oxygen radicals in human polymorphonuclear cells, which ...

DNA's double helix has long stood as the symbol of life’s code. But buried within the genome lies a deeper level of ...

Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

SLC35B1 transports ATP into the ER, and its structure offers potential for targeted therapies in diseases linked to ER stress ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

National Institutes of Health Director Jay Bhattacharya claimed the dean of Stanford Medical School asked him to stop ...

The appendix may play a further role in protecting the gastrointestinal system from invading pathogens. This would explain why surgical removal of the appendix has been associated with a worse ...